Amgen Seeks To Knock Out Humira Patents Through IPR Process
This article was originally published in The Pink Sheet Daily
Biosimilar sponsors are taking a shine to PTO’s new patent challenge proceedings.
You may also be interested in...
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.